• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Promising early results for BMS’ investigational HCC study pharmatimes
    June 05, 2019
    Bristol-Myers Squibb (BMS) has announced the first results from its investigational Opdivo (nivolumab) plus Yervoy (ipilimumab) cohorts of the Phase I/II CheckMate -040 study at the American Society of Clinical Oncology (ASCO) meeting 2019.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service